Blog


The Eagle Biosciences’ Calprotectin ELISA Kit was utilized in a recent study! Scientists explored whether the repeated clearance of colon microbiome for regular screenings or surgeries changes the microbiome. Check out the abstract and access to the full text below.


Abstract

Chronic gastrointestinal diseases are a significant global health burden that can require the use of gastrointestinal-cleansing regimens for diagnostics or therapeutic treatment. These regimens are beneficial for facilitating surgical preparation, drug delivery, colorectal cancer screenings, and personal use is common among proponents of natural health and among certain populations at high risk of HIV acquisition. It remains unclear, however, whether repeated clearance of the colonic microbiome induces persistent changes in the microbiome, intestinal immunity, and viral disease susceptibility. We addressed these parameters by repeatedly administering iso-osmolar enemas to rhesus macaques prior to low-dose intra-rectal challenge with simian immunodeficiency virus (SIV). Considering both longitudinal and cross-sectional analyses, we observed no consistent changes in the fecal microbiome or intestinal immune parameters of treated animals, nor were significant differences observed in susceptibility to SIV acquisition. Unexpectedly, enema-treated animals exhibited significantly lower setpoint viral loads after infection, although we were unable to clearly identify attributing causes. Our study demonstrates that repeated microbiome clearance using clinically administered iso-osmolar enemas is not sufficient to restructure the fecal microbiome, perturb intestinal immune parameters, or increase susceptibility to mucosal SIV challenge. This research framework serves as a model for the development of colonic-administered diagnostics like Calprotectin ELISA and interventions.

Ortiz, Alexandra M. et al. Repeated enema administration in rhesus macaques is not sufficient to promote bacterial dysbiosis or gastrointestinal dysfunction. Mucosal Immunology, Volume 0, Issue 0. doi: 10.1016/j.mucimm.2025.06.002


If you have any questions about this Calprotectin ELISA assay kit or any of our other offerings, contact Eagle Biosciences here.


Sclerostin is a bioactive glycoprotein primarily secreted by osteocytes that plays a crucial role in regulating bone formation and remodeling. It acts as an antagonist of the Wnt/β-catenin signaling pathway, binding to LRP5/6 co-receptors and inhibiting osteoblast activity, thereby reducing bone formation. Because of this regulatory function, sclerostin helps maintain skeletal homeostasis but also contributes to bone loss when present in excess, as seen in conditions like osteoporosis. Its bioactivity has made it a significant therapeutic target—most notably in the development of sclerostin-inhibiting monoclonal antibodies, which enhance bone formation and improve bone mineral density.

Biomedica’s Bioactive Sclerostin ELISA Kit was highlighted in a recent study investigating the association of total and bioactive serum Sclerostin levels with bone metabolism in type 2 diabetes mellitus (T2DM).  Click below for the full publications, where you can find the abstracts and key findings!

Traechslin, Cyril, et al. “Association of total and bioactive serum sclerostin levels with bone metabolism in type 2 diabetes mellitus.” Journal of Clinical & Translational Endocrinology, vol. 40, June 2025, p. 100393, https://doi.org/10.1016/j.jcte.2025.100393.


If you have any questions about this Bioactive Sclerostin ELISA assay kit or any of our other offerings, contact Eagle Biosciences here.

Serotonin Sensitive ELISA Kit


Abstract

Introduction: Serotonin (5-HT) is critical for neurodevelopment and the serotonin transporter (SERT) modulates serotonin levels. Perturbed prenatal and postnatal dietary exposures affect the developing offspring predisposing to neurobehavioral disorders in the adult. We hypothesized that the postnatal brain 5-HT-SERT imbalance associated with gut dysbiosis forms the contributing gut-brain axis dependent mechanism responsible for such ultimate phenotypes.

Methods: Employing maternal diet restricted (IUGR, n=8) and high fat+high fructose (HFhf, n=6) dietary modifications, rodent brain serotonin was assessed temporally by ELISA and SERT by quantitative Western blot analysis. Simultaneously, colonic microbiome studies were performed.

Results: At early postnatal (P) day 2 no changes in the IUGR, but a ~24% reduction in serotonin (p = 0.00005) in the HFhf group occurred, particularly in the males (p = 0.000007) revealing a male versus female difference (p = 0.006). No such changes in SERT concentrations emerged. At late P21 the IUGR group reared on HFhf (IUGR/HFhf, (n = 4) diet revealed increased serotonin by ~53% in males (p = 0.0001) and 36% in females (p = 0.023). While only females demonstrated a ~40% decrease in serotonin (p = 0.010), the males only trended lower without a significant change within the HFhf group (p = 0.146). SERT on the other hand was no different in HFhf or IUGR/RC, with only the female IUGR/HFhf revealing a 28% decrease (p = 0.036). In colonic microbiome studies, serotonin-producing Bacteriodes increased with decreased Lactobacillus at P2, while the serotonin-producing Streptococcus species increased in IUGR/HFhf at P21. Sex-specific changes emerged in association with brain serotonin or SERT in the case of Alistipase, Anaeroplasma, Blautia, Doria, Lactococcus, Proteus, and Roseburia genera.

Discussion: We conclude that an imbalanced 5-HT-SERT axis during postnatal brain development is sex-specific and induced by maternal dietary modifications related to postnatal gut dysbiosis. We speculate that these early changes albeit transient may permanently alter critical neural maturational processes affecting circuitry formation, thereby perturbing the neuropsychiatric equipoise.

Ye X et al. (2024) Brain serotonin and serotonin transporter expression in male and female postnatal rat offspring in response to perturbed early life dietary exposures. Front. Neurosci. 18:1363094. doi: 10.3389/fnins.2024.1363094


If you have any questions about this product or any of our other offerings, contact us here.

The Dopamine Sensitive ELISA Assay was utilized in a recent study! The study explored the effects of probiotics on olanzapine-induced metabolic syndrome through the gut microbiota. For more details, reference the abstract and access to the full text below.


Abstract

Background

Maintaining gut microbial homeostasis is crucial for human health, as imbalances in the gut microbiota (GM) can lead to various diseases, including metabolic syndrome (MS), exacerbated by the use of antipsychotic medications such as olanzapine (OLZ). Understanding the role of the GM in OLZ-induced MS could lead to new therapeutic strategies. This study used metagenomic analysis to explore the impact of OLZ on the GM composition and examined how probiotics can mitigate its adverse effects in a rat model. Changes in weight, blood pressure, and lipid levels, which are key parameters defining MS, were assessed. Additionally, this study investigated serotonin, dopamine, and histopathological changes to explore their possible link with the microbiota-gut-brain axis (MGBA).

Results

OLZ had an antagonistic effect on serotonin and dopamine receptors, and it was consistently found to alter the composition of the GM, with an increase in the relative abundance (RA) of the Firmicutes/Bacteroidetes phyla ratio and TM7 genera, indicating that the anticommonsal action of OLZ affects appetite and energy expenditure, contributing to obesity, dyslipidemia and increased blood pressure, which are core components of MS. Hepatic steatosis and intestinal damage in OLZ-treated rat tissues further indicate its role in MS. Conversely, the administration of probiotics, either alone or in combination with OLZ, was found to mitigate these OLZ-induced symptoms of MS by altering the GM composition. These alterations included increases in the abundances of the taxa BacteroidetesActinobacteriaPrevotellaBlautiaBacteroidesBacteroidales, and Ruminococcaceae and a decrease in Firmicute abundance. These changes helped maintain gut barrier integrity and modulated neurotransmitter levels, suggesting that probiotics can counteract the adverse metabolic effects of OLZ by restoring the GM balance. Moreover, this study highlights the modulation of the MGBA by OLZ as a potential mechanism through which probiotics modulate serotonin and dopamine levels, influencing metabolic health.

Conclusion

These findings emphasise the significant impact of OLZ on the GM and its contribution to MS. These findings suggest that interventions targeting the GM, such as probiotics, could mitigate the metabolic side effects of OLZ. Future research should focus on developing integrative treatment approaches that consider the health of the gut microbiome in managing antipsychotic-induced adverse effects.


If you have any questions about this product or any of our other offerings, contact us here.


The Calprotectin ELISA Kit was utilized in a recent publication. Scientists investigated the impact of repeated microbiome elimination on intestinal immunity and disease susceptibility. Check out the abstract and access to the full text below.


Abstract

Chronic gastrointestinal diseases are a significant global health burden that can require the use of gastrointestinal-cleansing regimens for diagnostics or therapeutic treatment. These regimens are beneficial for facilitating surgical preparation, drug delivery, colorectal cancer screenings, and personal use is common among proponents of natural health and among certain populations at high risk of HIV acquisition. It remains unclear, however, whether repeated clearance of the colonic microbiome induces persistent changes in the microbiome, intestinal immunity, and viral disease susceptibility. We addressed these parameters by repeatedly administering iso-osmolar enemas to rhesus macaques prior to low-dose intra-rectal challenge with simian immunodeficiency virus (SIV). Considering both longitudinal and cross-sectional analyses, we observed no consistent changes in the fecal microbiome or intestinal immune parameters of treated animals, nor were significant differences observed in susceptibility to SIV acquisition. Unexpectedly, enema-treated animals exhibited significantly lower setpoint viral loads after infection, although we were unable to clearly identify attributing causes. Our study demonstrates that repeated microbiome clearance using clinically administered iso-osmolar enemas is not sufficient to restructure the fecal microbiome, perturb intestinal immune parameters, or increase susceptibility to mucosal SIV challenge. This research framework serves as a model for the development of colonic-administered diagnostics and interventions.

Ortiz, Alexandra M. et al. Repeated enema administration in rhesus macaques is not sufficient to promote bacterial dysbiosis or gastrointestinal dysfunction. Mucosal Immunology, Volume 0, Issue 0. doi: 10.1016/j.mucimm.2025.06.002


If you have any questions about this product or any of our other offerings, contact us here.

Eagle Biosciences is excited to partner with BPM and support the Fetuin A (PTM) ELISA (DNlite-DKD)!


About Fetuin A (PTM)

The unique Fetuin A post translation modifications measured in this assay were identified in a large-scale profiling of urinary proteomics. This new biomarker can help predict the kidney condition of diabetes patients, months to years in advanced. This urine test can help predict kidney decline or complications and potentially improve a patient with diabetic kidney disease quality of care.

Principle of the Fetuin A (PTM) ELISA

The Fetuin A (PTM) ELISA (unique Fetuin-A with specific post translational modification (PTM) for Diabetic Kidney Disease (DKD)) is a competitive immunoassay. In this Fetuin A (PTM) ELISA, calibrators or unknown urine samples are mixed with anti-unique PTM Fetuin-A monoclonal antibody (mAb), and then incubated in a microplate pre-bounded with unique PTM Fetuin-A. The monoclonal antibody recognizes unique PTM Fetuin-A in calibrators or unknown samples under competition in microplate wells. After an incubation, an Horseradish Peroxide (HRP) conjugated secondary antibody is added, followed by an incubation with 3,3’,5,5’-tetramethylbenzidine (TMB) substrate. Their relative reactivity is determined by absorbance measurement at 450 nanometers (nm) and plotted by comparison with a predetermined unique PTM Fetuin-A calibration curve.

Benefits of the Assay

    • Fewer Steps
    • Shorter processing times – ever for high-throughput samples

If you have any questions about this kit or any of our other offerings, contact us here.

What are MHC molecules?

Major histocompatibility complex (MHC) molecules play an important role in the acquired immune system of vertebrates. MHC molecules present peptides derived from pathogens on the cell surface so that T-cells can determine the appropriate immune response. The MHC also plays a role in mediating leukocyte interactions, determining compatibility for organ transplants, and determining autoimmune disease susceptibility. In humans, the MHC complex is also known as the human leukocyte antigen (HLA) complex.

The peptide-MHC (pMHC) interaction to cognate T-cell receptors (TcR) occurs rapidly and at low affinity. Tetramerizing these molecules on a streptavidin scaffold engages multiple TcRs expressed on a given T cell, which stabilizes the reaction and allows for specific T cell staining. pMHC monomers and tetramers can also be used for purification and manipulation of T cells.


Research Applications

MHC monomers and tetramers can be used for selection and proliferation of specific T cells, allowing researchers to isolate specific viral or tumor related antigens. These antigens can be reintroduced to augment the immune system. They are also used in organ transplant research to help reduce the risk of graft-versus-host disease. Additionally, researchers in cancer immunotherapy and vaccine development are exploring various MHC multimer applications to further their fields.


What Eagle Biosciences Offers

We offer a wide range of pMHC monomers and tetramers through our partner, ImmunAware, including easYmer MHC tetramer kits. All of the MHC molecules in are catalog are biotinylated, meaning all of the pMHC monomers can be tetramerized with the laboratory’s choice of strepatavidin label.

View all of our monomer, tetramer, and easYmer kits here.


For more information or assistance finding a specific product, please contact us.

Eagle Biosciences is excited to announce the newest product series for Host Cell Protein Detection!

Host cell proteins (HCPs) are a major class of impurities produced during biotherapeutic manufacturing. They must be removed from the final drug product to both assure patient safety and maintain drug efficacy. Our wide range of Host Cell Protein Detection Kits are easy to use and highly sensitive.


What are HCPs and why must they be removed from biologic drugs?

HCPs are proteins produced or encoded by the host organisms used to produce recombinant therapeutic proteins. Genetic engineering allows the host organism cells to be transformed to produce a protein of interest. During the recombinant protein production, host cells also coproduce proteins related to the normal cell functions such structural proteins, as well as proteins required for normal cellular growth and function, and vary in both number and concentration depending on the chosen host species and the manufacturing process being used. In general, apart from the therapeutic protein of interest, all endogenous proteins co-expressed by the host cells are called host-cell proteins.

Why must HCPs be removed from biologic drugs?

HCPs must be removed from the final biotherapeutic product to avoid adverse effects. Almost all HCPs carry safety risks as foreign proteins due to the potential to elicit immune response in humans (e.g, cytokine storm). In addition, some HCPs can also act to enhance the immune response to a drug product. Certain HCPs can also affect drug product stability and efficacy if not adequately removed or inactivated.

How are HCPs detected?

ELISAs are widely used for detecting HCPs, where they are generally configured in a sandwich assay format for improved specificity. In this scenario, a microplate-bound antibody is used for analyte capture, then a second analyte-specific antibody (that binds a different epitope on the target molecule) is added to enable detection. By incorporating a reference standard (e.g., a purified protein) into the assay design, it is possible to quantify the analyte of interest and confirm that its concentration meets regulatory requirements. Advantages of ELISA are that it is sensitive and compatible with high sample throughput – key considerations for biopharmaceutical manufacturing.


If you have any questions about these products or any of our other offerings, contact us here.


The measurement of cell proliferation and cell toxicity is fundamental in biomedical research, especially in fields such as cancer biology, pharmacology, and toxicology. These parameters provide essential information about cell health, growth dynamics, and the effects of external agents such as drugs, environmental toxins, or genetic modifications.

Biomedica’s EZ4U ELISA Assay Kit (BI-5000) was highlighted in a recent study that investigated the development of novel chemosensitizers targeting therapy-resistant cancer stem cells (CSCs). The metabolic activity of cells was assessed using various cell lines. The study shows that telmisartan derivatives serve as effective chemosensitizers and offer an innovative approach for targeting CSCs in different types of malignant diseases. Click below for the full publication, where you can find the abstract and key findings!

Eradication of Therapy-Resistant Cancer Stem Cells by Novel Telmisartan Derivatives. Schoepf Anna M. et al., J Med Chem. 2025; 68(1):287-306


If you have any questions about this kit or any of our other offerings, contact us here.

The DHEA ELISA Kit was highlighted in recent publication that explored how low psychological resilience and physical fitness predict attrition from US Marine Corps Officer Candidate School training! For more details, reference the abstract and access the full text below.


Abstract

The objective is to examine the predictors of attrition in male and female candidates undergoing a 10-week early career military training program. 1006 candidates (79.5% male, 24.7 ± 3.2 years) consented to participating in a larger study examining predictors of injury during US Marine Corps Officer Candidates School (OCS). Participants completed a blood draw, demographic and psychological characteristics questionnaires, and two fitness tests. Participants were then grouped based on successful completion of OCS or not. Associations between potential predictors and attrition were analyzed using simple logistic regression analyses, followed by a backward stepwise elimination method. Area under the curve (AUC) of the receiver operating characteristic (ROC) curve was used to determine the accuracy of the attrition prediction model. 260 candidates (25.8%) attritted over the 10-week training, with the highest number of discharges during week 5. Musculoskeletal injury (MSKI) was the most common cause of attrition (30%), followed by non-MSKI medical (21.5%), and volitional withdrawals (19.6%). Sex, body mass index (BMI), resilience, initial physical fitness test score, combat fitness test (CFT) score, and prior military service were all significantly associated with attrition from OCS (all p < .05). The final prediction model of attrition included CFT score (p = .027) and resilience (p = .018). Multiple demographic, psychological, and fitness characteristics are associated with attrition from an early career military training course (OCS) and may be utilized as part of early screening procedures to identify and provide guidance for individuals at risk for not completing OCS.


If you have any questions about this DHEA ELISA kit or any of our other offerings, contact Eagle Biosciences here.